Phase 1 Study of Inhaled Peptide Therapy for Cystic Fibrosis Begins
The study will evaluate the safety and tolerability of an inhaled peptide therapy designed to enhance CFTR function, act as a bronchodilator, and reduce inflammation.
The study will evaluate the safety and tolerability of an inhaled peptide therapy designed to enhance CFTR function, act as a bronchodilator, and reduce inflammation.
The study will evaluate the safety and tolerability of an inhaled peptide therapy designed to enhance CFTR function, act as a bronchodilator, and reduce inflammation.
Read MoreThe NIH clinical trial aims to address a knowledge gap on mpox vaccine use in adolescent populations.
Read MoreThe FDA has placed a hold on Novavax’s Investigational New Drug application for its COVID-19-influenza combination and stand-alone influenza vaccines following a report of an adverse event in a participant from the completed combination trial.
Read MoreThe trial will assess the efficacy of the drug, which has been granted orphan drug designation, when added to the standard of care in preventing or reducing the severity of bronchopulmonary dysplasia.
Read MoreNew sub-analyses show that brensocatib reduced pulmonary exacerbations and slowed lung function decline for most subgroups of patients with non-cystic fibrosis bronchiectasis.
Read MoreCumulative efficacy over three RSV seasons was clinically meaningful at 62.9% against RSV-LRTD after a single dose of the vaccine.Â
Read MoreAstraZeneca’s inhaled anti-inflammatory rescue medication demonstrated significant benefit compared to albuterol in a phase IIIb trial.
Read MoreTopline results demonstrated that the drug was well-tolerated over a 10-day period and achieved consistent plasma levels without the need for ritonavir co-administration.Â
Read MoreThe radiofrequency ablation treatment indicated for chronic rhinitis led to significant improvements in rhinitis, as well as ear symptoms, at six-month follow-up.
Read MoreETD001 aims to improve lung function by targeting mucus clearance in patients with high unmet medical needs.
Read MoreA phase III study demonstrated that a single oral dose of Xofluza significantly reduced the spread of influenza within households.
Read MoreApnimed announced the early completion of enrollment for its phase 3 trial to evaluate the efficacy and safety of AD109 for obstructive sleep apnea.
Read MoreNIH-backed research reveals diabetics taking metformin have a lower risk of developing long COVID or dying after infection compared to those on other diabetes medications.
Read MoreData shows that metered cryospray therapy with the investigational RejuvenAir System leads to airway remodeling and improved symptoms in chronic bronchitis patients.
Read MoreThe 12-month study will assess how a digital platform designed for asthma management impacts symptom control, medication adherence, and healthcare utilization in patients with moderate to severe asthma.
Read MoreData from a post hoc analysis of a phase 2/3 study of oral opaganib in COVID-19 pneumonia showed a 62% reduction in mortality and a 21% improvement in time to room air.
Read MoreThe phase 2 study will evaluate the safety and efficacy of ARCT-032, an inhaled mRNA therapy for cystic fibrosis patients, which previously received Orphan Drug Designation.
Read MoreThe first patients have been treated in a study evaluating the safety of an ultrasound-based lung denervation technique for treating COPD and asthma.
Read MoreThe vaccine candidate showed strong responses against influenza A and COVID-19 but did not meet its goal for influenza B.
Read MoreThe FDA granted Fast Track designation to Deltacel, a Gamma Delta T-cell therapy being developed for the treatment of advanced non-small cell lung cancer.
Read MoreThe phase 1 trials are evaluating two NBD1 stabilizers, SION-719 and SION-451, which are designed to improve CFTR protein function in cystic fibrosis patients.
Read MoreThe EBO-301 study is being discontinued following topline results from the phase 2 part of the study in treatment-refractory patients with MAC lung disease.
Read MorePfizer’s Abrysvo demonstrated a strong immune response and favorable safety profile in immunocompromised adults at high risk of severe RSV.
Read MoreThe phase 3 trial was investigating the vibostolimab and pembrolizumab combination with chemotherapy for first-line treatment of extensive-stage small cell lung cancer.
Read More